FLUDD — Late Stage Fluorination and its Applications to Drug Discovery

Results in brief

Late Stage Fluorination and its Applications to Drug Discovery

Modern medicine is dependent on advances in chemistry. There is spreading of infectious diseases with drug resistance growing in all countries. In addition to this the increasing cases of non-infectious diseases in an ageing population brings further challenges to healthcare. Among the challenges to developing better healthcare are: 1) lack of basic molecular level understanding of the disease biology, 2) lack of sufficiently advanced tools and methods to detect, monitor the progression and treat diseases, 3) an insufficient array of chemical tools to interrogate and validate novel disease relevant targets, 4) lack of an arsenal of both small and large molecules able to engage drug targets in vivo and thereby ameliorating diseases. Overcoming these challenges can be facilitated through stronger links between universities and the pharmaceutical companies. The FLUDD Consortia including 2 academic and 1 industrial beneficiaries, aims to train 5 PhD students for a chemistry career in industry. With training in the development of novel late stage fluorination chemistry to populate the chemical and radiochemical space available for drug discovery. With the main focus on novel fluorine-containing fragments, molecules and biomolecules that are not commercially available but required to advance modern medicine. The research within the FLUDD European Industrial Doctorate (EID) is focused on the following scientific and educational objectives. The scientific objectives - Develop novel late stage fluorination chemistry for drug discovery - Focus on novel fluorine-containing fragments, molecules and biomolecules The educational objectives - To train the next generation of doctoral scientists - Training in the practice of chemical synthesis and radiochemical methods - Gain an in-depth appreciation of their applications in medicine

Data: CORDIS, © European Union

Project objective

All of modern medicine is dependent on advances in chemistry and the healthcare goalposts have moved as the century has progressed. The pressing need to shorten cycle times and reduce the costs of drug discovery has led pharma and the clinicians that guide them to use scanning techniques such as positron emission tomography (PET), enabling them to increase disease understanding, study target engagement with therapeutics and improve decision making, so that only the best candidate molecules progress to the later stages of drug development. Overcoming these challenges requires multidisciplinary knowledge, and can be facilitated through stronger links between academia and Pharma. Chemical entities substituted with fluorine or fluorine-containing groups are frequently used to design drugs with improved pharmacological and pharmacokinetic profiles that provide important benefits over existing therapies, such as superior safety, efficacy, dosing, and patient compliance. Furthermore, 18F is often selected as the preferred positron-emitting isotope for the labeling of PET tracers due to its advantageous properties. The scientific objective of FLUDD is to develop novel late stage fluorination chemistry to populate the chemical and radiochemical space available for drug discovery with a focus on novel fluorine-containing fragments, molecules and biomolecules that are not directly accessible from commercial sources or the scientific literature. These novel methodologies will be applied to drugs and diagnostics discovery using both small molecules and proteins. The educational objective is to train the next generation of doctoral scientists in the practice of chemical synthesis and radiochemical methods with an in-depth appreciation of their applications in medicine. FLUDD objectives will be met with a novel Oxford-Janssen Alliance augmented with leading partners from academia, industry and the clinic.

Original text from CORDIS.

Participants

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD · OxfordCoordinatorUnited Kingdom
JANSSEN CILAG SA · MadridSpain

FLUDD · Late Stage Fluorination and its Applications to Drug Discovery

Results in brief

Late Stage Fluorination and its Applications to Drug Discovery

Project objective

Participants

Links